| [1]SHAW L J,BERMAN D S,MARON D J,et al.Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden:results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation(COURAGE)trial nuclear substudy[J].Circulation,2008,117(10):1283-1291.
[2]HOBBS F D,ROALFE A K,DAVIS R C,et al.Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction:5 year mortality follow-up of the Echocardiographic Heart of England Screening Study(ECHOES)[J].Eur Heart J,2007,28(9):1128-1134.
[3]GHEORGHIADE M,VADUGANATHAN M,FONAROW G C,et al.Rehospitalization for heart failure:problems and perspectives[J].J Am Coll Cardiol,2013,61(4):391-403.
[4]GHEORGHIADE M,ABRAHAM W T,ALBERT N M,et al.Systolic blood pressure at admission,clinical characteristics,and outcomes in patients hospitalized with acute heart failure[J].JAMA,2006,296(18):2217-2226.
[5]WANG X,LIU Y,YUAN Y,et al.Short-term prognostic factors in the patients after acute heart failure[J].Int J Clin Exp Med,2015,8(1):1515-1520.
[6]MCMURRAY J J,ADAMOPOULOS S,ANKER S D,et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association(HFA)of the ESC[J].Eur Heart J,2012,33(14):1787-1847.
[7]SHIBA N,NOCHIOKA K,MIURA M,et al.Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan-First report from the CHART-2 Study[J].Circ J,2011,75(4):823-833.
[8]SAKATA Y,SHIMOKAWA H.Epidemiology of heart failure in Asia[J].Circ J,2013,77(9):2209-2217.
[9]KAILA K,HAYKOWSKY M J,THOMPSON R B,et al.Heart failure with preserved ejection fraction in the elderly:scope of the problem[J].Heart Fail Rev,2012,17(4/5):555-562.
[10]OWAN T E,HODGE D O,HERGES R M,et al.Trends in prevalence and outcome of heart failure with preserved ejection fraction[J].N Engl J Med,2006,355(3):251-259.
[11]ZILE M R,GAASCH W H,PATEL K,et al.Adverse left ventricular remodeling in community-dwelling older adults predicts incident heart failure and mortality[J].JACC Heart Fail,2014,2(5):512-522.
[12]MASSON S,LATINI R,ANAND I S,et al.Direct comparison of B-type natriuretic peptide(BNP)and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure:the Valsartan Heart Failure(Val-HeFT)data[J].Clin Chem,2006,52(8):1528-1538.
[13]WALDO S W,BEEDE J,ISAKSON S,et al.Pro-B-type natriuretic peptide levels in acute decompensated heart failure[J].J Am Coll Cardiol,2008,51(19):1874-1882.
[14]BROUWERS F P,HILLEGE H L,VAN GILST W H,et al.Comparing new onset heart failure with reduced ejection fraction and new onset heart failure with preserved ejection fraction:an epidemiologic perspective[J].Curr Heart Fail Rep,2012,9(4):363-368.
[15]MENTZ R J,KELLY J P,VON LUEDER T G,et al.Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction[J].J Am Coll Cardiol,2014,64(21):2281-2293.
[16]HO J E,LYASS A,LEE D S,et al.Predictors of new-onset heart failure:differences in preserved versus reduced ejection fraction[J].Circ Heart Fail,2013,6(2):279-286.
[17]ATHER S,CHAN W,BOZKURT B,et al.Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction[J].J Am Coll Cardiol,2012,59(11):998-1005.
[18]LEE D S,GONA P,VASAN R S,et al.Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction:insights from the framingham heart study of the national heart,lung,and blood institute[J].Circulation,2009,119(24):3070-3077.
[19]DAVIS B R,KOSTIS J B,SIMPSON L M,et al.Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial[J].Circulation,2008,118(22):2259-2267.
[20]GUPTA D K,SHAH A M,CASTAGNO D,et al.Heart failure with preserved ejection fraction in African Americans:the ARIC(Atherosclerosis Risk in Communities)study[J].JACC Heart Fail,2013,1(2):156-163.
[21]PEACOCK F,AMIN A,GRANGER C B,et al.Hypertensive heart failure:patient characteristics,treatment,and outcomes[J].Am J Emerg Med,2011,29(8):855-862.
[22]TROUGHTON R,MICHAEL FELKER G,JANUZZI J L.Natriuretic peptide-guided heart failure management[J].Eur Heart J,2014,35(1):16-22.
[23]PFISTER R,SCHNEIDER C A.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008:application of natriuretic peptides[J].Eur Heart J,2009,30(3):382-383. |